{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-001890","form_type":"8-K","ticker":"BYSI","cik":"0001677940","company_name":"BeyondSpring Inc.","filed_at":"2026-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.866431+00:00","generated_at":"2026-05-15T09:01:55.010362+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BeyondSpring reports FY2025 net loss $8.7M; Plinabulin Phase 3 survival benefit confirmed, DUBLIN-4 planned","bullets":["R&D expense $4.4M, G&A $4.6M; cash $12.6M as of Dec 31, 2025.","Plinabulin+docetaxel achieved OS HR 0.72 in non-squamous NSCLC; DUBLIN-4 confirmatory trial planned.","SEED Therapeutics dosed first patient in Phase 1a for ST-01156; completed $30M Series A-3 financing.","Sold portion of SEED preferred shares for ~$35.4M gross proceeds; first closing $7.35M in Feb 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-001890","json":"https://secwatch.observer/filing/0001171843-26-001890.json","markdown":"https://secwatch.observer/filing/0001171843-26-001890.md","text":"https://secwatch.observer/filing/0001171843-26-001890.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677940/000117184326001890/0001171843-26-001890-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677940/000117184326001890/f8k_032526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:01:55.010362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b0fd96d60baa3ac24bb58efd8c16d493c99224e","claim":"BeyondSpring Inc. reported financial results for the full year ended December 31, 2025.","evidence_excerpt":"On March 25, 2026, BeyondSpring Inc. (the “Company”) issued a press release announcing its financial results for the full year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1677940/000117184326001890/0001171843-26-001890-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}